To gather insights into CRO industry trends, Tufts CSDD
conducted interviews with eleven senior executives at four of the top 10 CROs by revenue.
It should be noted, however, that few symptoms of depression were recorded on any of the CSDD
Using the CSDD
, an instrument specifically designed for patients with dementia, Vida et al (22) found good accuracy for detecting depression; however, they studied patients with relatively mild dementia.
In a study published in 2003, Tufts CSDD
estimated the cost per approved new chug at $802 million (in 2000 dollars) for drugs first tested in human subjects from 1983 to 1994, based on average out-of-pocket costs of $403 million and capital costs of $401 million.
The analysis, published in the November/December Tufts CSDD
Impact Report, also found that the number of biotech products in clinical trials grew 155% in 11 years, from 355 in 2001 to 907 in 2012, with Big Pharma in 2012 engaged in about 40% of all biotech products in clinical development.
The R&D Leadership Summit offers a rare opportunity for senior level pharmaceutical and biotechnology executives to discuss the most critical issues and opportunities companies are facing and the solutions that they are considering and implementing," said Kenneth Getz, Senior Research Fellow, Tufts CSDD
and conference facilitator.
FDA requires post-approval studies as a condition of approval, and according to Tufts CSDD
, these costs of $312 million bring the full product lifecycle cost per drug, on average, to $2.
That number increased to an average of five per year in the 2009-2012 period, according to Tufts CSDD
The article, included in the May issue of the Journal of Health Economics, contains more detailed analyses than what was presented in November 2014 when Tufts CSDD
first disclosed primary results on drug development costs, after having previously submitted the study to the peer-reviewed publication.
said its recent analysis, based on more than 150 clinical studies involving nearly 16,000 sites, will help clinical research professionals plan and manage clinical trials better.
it is not clear if greater access leads to better health outcomes," noted Joshua Cohen, research assistant professor at Tufts CSDD
, who conducted the analysis.
Ken Getz of Tufts CSDD
to deliver keynote in half-day seminars on May 1-3, 2007